+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome

Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome

Journal of Immunology 140(6): 1883-1888

A major sequela of immunotherapy with interleukin 2 (IL-2) is development of a vascular leak syndrome. The pathogenesis of this toxic effect is not known. We have examined pre- and post-treatment skin biopsies from 14 patients undergoing systemic administration of IL-2 for evidence of endothelial cell activation. Specifically, we have used the immunoperoxidase technique to detect the expression of three different activation antigens: endothelial-leukocyte adhesion molecule 1, detected with monoclonal antibody H4/18; intercellular adhesion molecule1, detected with antibody RR1/1; and histocompatibility leukocyte antigen-DQ, detected with antibody Leu 10. Each of these antigens may be induced on cultured endothelial cells by various cytokines (although not by IL-2) and is expressed during endothelial cell activation in vivo at sites of delayed hypersensitivity and other immune responses. Pretreatment biopsies from each patient showed no endothelial expression of endothelial-leukocyte adhesion molecule 1 and only weak to lmoderate expression of intercellular adhesion molecule 1 and histocompatibility leukocyte antigen-DQ (except for one specimen unreactive with Leu 10). After 5 days of treatment, every patient showed marked endothelial expression of all three antigens (except for the same patient who remained unreactive with Leu 10). Endothelial-leukocyte adhesion molecule-1 expression was confined to postcapillary venular endothelium whereas intercellular adhesion molecule-1 and Leu 10 also were expressed on stromal cells and mononuclear cells. Thus, we conclude that i.v. administration of IL-2 leads to endothelial cell activation. Because IL-2 fails to induce the same antigens on cultured endothelial cells, we infer that IL-2 acts in vivo by inducing the production of other cytokines (e.g., interleukin 1, tumor necrosis factor, lymphotoxin, and interferon-.GAMMA.). Finally, since endothelial cell activation at sites of cell-mediated immune responses is well known to result in vascular leakiness to macromolecules, we propose that the vascular leak syndrome accompanying IL-2 therapy may arise from widespread inappropriate endothelial cell activation.

(PDF emailed within 1 workday: $29.90)

Accession: 005359853

Download citation: RISBibTeXText

PMID: 3279124

Related references

Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome. International Journal of Biological Markers 5(4): 195-197, 1990

Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome. Journal of ImmunoTherapy 34(5): 419-427, 2011

Interleukin 2 activation of neutrophil adherence to HUVEC as a possible model for vascular leak syndrome. Proceedings of the American Association for Cancer Research Annual Meeting 36(0): 498, 1995

Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proceedings of the National Academy of Sciences of the United States of America 96(7): 57-62, 1999

An ultrastructural study of in vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2. Cancer 68(10): 2169-2174, 1991

Interleukin 2 induced vascular leak syndrome in mice is secondary to endothelial cytotoxicity mediated by lymphokine activated killer lak cells. Laboratory Investigation 60(1): 3A, 1989

Lymphokine activated killer (LAK) cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2. Transactions of the Association of American Physicians 100: 21-27, 1987

Vascular leak syndrome: A side effect of immunotherapy. Immunopharmacology 37(2-3): 117-132, 1997

Vascular leak syndrome A troublesome side effect of immunotherapy. Immunopharmacology 39(3): 255, 257, June, 1998

Interleukin-1 alpha reduces the severity of the vascular leak syndrome produced by interleukin-2 and interleukin-2 plus interferon-alpha. Toxicologic Pathology 22(4): 381-397, 1994

Vascular leak syndrome: a troublesome side effect of immunotherapy, Immunopharmacology, 39/3 (1998) 255. Immunopharmacology 39(3): 255, 257-255, 257, 1998

Pathogenesis of the interleukin-2-induced vascular leak syndrome. Atkins, M B, Mier, J W Basic and Clinical Oncology; Therapeutic applications of interleukin-2: 363-379, 1993

Vascular leak syndrome associated with interleukin-2: chest radiographic manifestations. Radiology 176(1): 191-194, 1990

Neutrophil activation, vascular leak toxicity, and cytolysis during interleukin-2 infusion in human cancer. Surgery (St Louis) 122(5): 918-926, 1997